Engineering the CYP101 system for in vivo oxidation of unnatural substrates

被引:68
作者
Bell, SG [1 ]
Harford-Cross, CF [1 ]
Wong, LL [1 ]
机构
[1] Univ Oxford, Inorgan Chem Lab, Dept Chem, Oxford OX1 3QR, England
来源
PROTEIN ENGINEERING | 2001年 / 14卷 / 10期
关键词
CYP101; in vivo; oxidation; P450(cam); pCW; putidaredoxin; putidaredoxin reductase; self-sufficient; whole-cell systems;
D O I
10.1093/protein/14.10.797
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The protein engineering of CYP enzymes for structure-activity studies and the oxidation of unnatural substrates for biotechnological applications will be greatly facilitated by the availability of functional, whole-cell systems for substrate oxidation. We report the construction of a tricistronic plasmid that expresses the CYP101 monooxygenase from Pseudomonas putida, and its physiological electron transfer co-factor proteins putidaredoxin reductase and putidaredoxin in Escherichia coli, giving a functional in vivo catalytic system. Wild-type CYP101 expressed in this system efficiently transforms camphor to 5-exo-hydroxycamphor without further oxidation to 5-oxo-camphor until > 95% of camphor has been consumed. CYP101 mutants with increased activity for the oxidation of diphenylmethane (the Y96F-I395G mutant), styrene and ethylbenzene (the Y96F-V247L mutant) have been engineered. In particular, the Y96F-V247L mutant shows coupling efficiency of approximately 60% for styrene and ethylbenzene oxidation, with substrate oxidation rates of approximately 100/min. Escherichia coli cells transformed with tricistronic plasmids expressing these mutants readily gave 100-mg quantities of 4-hydroxydiphenylmethane and 1-phenylethanol in 24-72 h. This new in vivo system can be used for preparative scale reactions for product characterization, and will greatly facilitate directed evolution of the CYP101 enzyme for enhanced activity and selectivity of substrate oxidation.
引用
收藏
页码:797 / 802
页数:6
相关论文
共 51 条
[31]   Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:Rat NADPH-cytochrome P450 reductase fusion protein [J].
Parikh, A ;
Guengerich, FP .
PROTEIN EXPRESSION AND PURIFICATION, 1997, 9 (03) :346-354
[32]   Drug metabolism by Escherichia coli expressing human cytochromes P450 [J].
Parikh, A ;
Gillam, EMJ ;
Guengerich, FP .
NATURE BIOTECHNOLOGY, 1997, 15 (08) :784-788
[33]  
PETERSON JA, 1990, J BIOL CHEM, V265, P6066
[34]   HIGH-RESOLUTION CRYSTAL-STRUCTURE OF CYTOCHROME-P450CAM [J].
POULOS, TL ;
FINZEL, BC ;
HOWARD, AJ .
JOURNAL OF MOLECULAR BIOLOGY, 1987, 195 (03) :687-700
[35]   CONTINUOUS PRODUCTION OF POLY(3-HYDROXYALKANOATES) BY PSEUDOMONAS-OLEOVORANS IN A HIGH-CELL-DENSITY, 2-LIQUID-PHASE CHEMOSTAT [J].
PREUSTING, H ;
HAZENBERG, W ;
WITHOLT, B .
ENZYME AND MICROBIAL TECHNOLOGY, 1993, 15 (04) :311-316
[36]   Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli [J].
Pritchard, MP ;
Glancey, MJ ;
Blake, JAR ;
Gilham, DE ;
Burchell, B ;
Wolf, CR ;
Fridberg, T .
PHARMACOGENETICS, 1998, 8 (01) :33-42
[37]   CRYSTAL-STRUCTURES OF CYTOCHROME-P-450CAM COMPLEXED WITH CAMPHANE, THIOCAMPHOR, AND ADAMANTANE - FACTORS CONTROLLING P-450 SUBSTRATE HYDROXYLATION [J].
RAAG, R ;
POULOS, TL .
BIOCHEMISTRY, 1991, 30 (10) :2674-2684
[38]  
Sambrook J., 1989, MOL CLONING
[39]  
Schneider S, 1998, APPL ENVIRON MICROB, V64, P3784
[40]  
Schneider S, 1998, TETRAHEDRON-ASYMMETR, V9, P2833